Jump to navigation Jump to search
Aleglitazar is a peroxisome proliferator-activated receptor agonist which is being developed by Hoffmann–La Roche for the treatment of type II diabetes. It is currently in phase II clinical trials.
- ClinicalTrials.gov. "A Study of Aleglitazar in Patients With Type 2 Diabetes". United States National Institutes of Health. Retrieved 2008-03-19.